Applied StemCell

Applied StemCell is a privately held, revenue-generating biotech tools and services company that has positioned itself as a critical enabler for the cell therapy industry. Its key differentiator is the TARGATT™ technology, a site-specific integration platform capable of efficiently inserting large DNA payloads (up to 50kb) into safe harbor loci, overcoming limitations of random integration and CRISPR-based homologous recombination. The company leverages this platform, alongside comprehensive iPSC services and cGMP cell banking, to support partners advancing next-generation therapies, with a clear strategic focus on allogeneic, off-the-shelf cell therapies. With over a decade of experience and thousands of successful projects, Applied StemCell functions as a specialized CDMO and technology provider bridging early research and clinical manufacturing.

Proprietary TARGATT™ serine integrase-based platform for site-specific, large cargo (up to 50+ kb) knock-in into safe harbor loci (e.g., H11). Also utilizes CRISPR, Mad7 nucleases, and offers full iPSC services (reprogramming, editing, differentiation) and cGMP cell banking.

Applied StemCell competes with large life science tools companies (e.g., Thermo Fisher, Lonza) offering cell engineering services, specialized gene editing CROs/CDMOs (e.g., GenScript, Charles River's Horizon Discovery), and other niche iPSC service providers. Its key differentiator is the patented TARGATT™ platform for efficient, large-scale knock-ins, a specific capability not widely available from larger, more generalized competitors.